MedTrace Logo

Androgen Deprivation Therapy Study

NCT00743327 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2012-08-06

No results posted yet for this study

Summary

The purpose of this study is to examine the link between low testosterone and insulin resistance/diabetes in men undergoing androgen deprivation therapy for prostate cancer. The study will also evaluate other cardiovascular risk factors in these men.

Conditions

Interventions

DRUG

Pioglitazone

45mg capsule, once daily for 1 year

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    lead NIH

Principal Investigators

  • Josephine M. Egan, MD · National Institute on Aging, Intramural Research Program

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00743327 on ClinicalTrials.gov